- Home
- TDF vs OABI Comparison
TDF vs OABI Comparison
Compare TDF & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TDF
- OABI
- Stock Information
- Founded
- TDF 1994
- OABI 2012
- Country
- TDF Singapore
- OABI United States
- Employees
- TDF N/A
- OABI N/A
- Industry
- TDF Finance/Investors Services
- OABI Biotechnology: Pharmaceutical Preparations
- Sector
- TDF Finance
- OABI Health Care
- Exchange
- TDF Nasdaq
- OABI Nasdaq
- Market Cap
- TDF 244.7M
- OABI 198.2M
- IPO Year
- TDF N/A
- OABI N/A
- Fundamental
- Price
- TDF $9.96
- OABI $1.93
- Analyst Decision
- TDF
- OABI Strong Buy
- Analyst Count
- TDF 0
- OABI 3
- Target Price
- TDF N/A
- OABI $7.00
- AVG Volume (30 Days)
- TDF 79.2K
- OABI 912.8K
- Earning Date
- TDF 01-01-0001
- OABI 08-07-2025
- Dividend Yield
- TDF N/A
- OABI N/A
- EPS Growth
- TDF N/A
- OABI N/A
- EPS
- TDF N/A
- OABI N/A
- Revenue
- TDF N/A
- OABI $26,744,000.00
- Revenue This Year
- TDF N/A
- OABI N/A
- Revenue Next Year
- TDF N/A
- OABI $45.65
- P/E Ratio
- TDF N/A
- OABI N/A
- Revenue Growth
- TDF N/A
- OABI 27.07
- 52 Week Low
- TDF $7.15
- OABI $1.22
- 52 Week High
- TDF $10.62
- OABI $4.96
- Technical
- Relative Strength Index (RSI)
- TDF 54.59
- OABI 69.01
- Support Level
- TDF $9.91
- OABI $1.55
- Resistance Level
- TDF $10.05
- OABI $1.73
- Average True Range (ATR)
- TDF 0.18
- OABI 0.10
- MACD
- TDF -0.01
- OABI 0.03
- Stochastic Oscillator
- TDF 73.97
- OABI 100.00
About TDF Templeton Dragon Fund Inc.
Templeton Dragon Fund Inc is a closed-end management investment company. The fund seeks long-term capital appreciation by investing majority of its total assets in equity securities of China companies. It invests in various sectors such as gas & consumable fuels, auto components, banks, beverages, communications equipment, healthcare equipment & supplies, restaurants & leisure, household durables and many others.
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.